Compare · A vs BRKR
A vs BRKR
Side-by-side comparison of Agilent Technologies Inc. (A) and Bruker Corporation (BRKR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and BRKR operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- A is the larger of the two at $47.41B, about 5.4x BRKR ($8.82B).
- A has been more active in the news (5 items in the past 4 weeks vs 3 for BRKR).
- A has more recent analyst coverage (25 ratings vs 23 for BRKR).
- Company
- Agilent Technologies Inc.
- Bruker Corporation
- Price
- $170.59+1.46%
- $58.80+1.57%
- Market cap
- $47.41B
- $8.82B
- 1M return
- -
- +9.81%
- 1Y return
- -
- +62.36%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 5
- 3
- Recent ratings
- 25
- 23
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Latest A
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
- SEC Form EFFECT filed by Agilent Technologies Inc.
- SEC Form 424B3 filed by Agilent Technologies Inc.
- Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control
- CORRECTING and REPLACING Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent Announces Cash Dividend of 25.5 Cents per Share
- Agilent to Participate in J.P. Morgan U.S. All Stars Conference
- Director Boehnlein Glenn S was granted 817 shares (SEC Form 4)
- New insider Boehnlein Glenn S claimed ownership of 35 shares (SEC Form 3)
Latest BRKR
- Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
- Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
- Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $105,740 worth of shares (2,000 units at $52.87) as part of a pre-agreed trading plan (SEC Form 4)
- UBS initiated coverage on Bruker with a new price target
- Bruker Corporation to Present at Upcoming Investor Conferences
- BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
- Chief Accounting Officer Bures Thomas was granted 4,035 shares, increasing direct ownership by 126% to 7,233 units (SEC Form 4)
- President BMID Group Pusch Wolfgang sold $197,614 worth of shares (3,473 units at $56.90) and was granted 3,120 shares, decreasing direct ownership by 3% to 9,801 units (SEC Form 4)
- EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N was granted 15,794 shares and covered exercise/tax liability with 2,724 shares, increasing direct ownership by 13% to 111,354 units (SEC Form 4) to cover taxes